Dr. Satheesh CT

Introduction

Expertise

• Dr. Satheesh is a consultant – medical and haemato oncology and the director of clinical trials at HCG Cancer Centre, Bengaluru.
• Dr. Satheesh’s key areas of experience include the treatment of various solid and haematological cancers with conventional, high-dose chemotherapy, targeted chemotherapy and immunotherapy.
• His other areas of specialisation include paediatric malignancies, lymphomas, and gynaecological cancers, along with breast and lung cancers and cancer genomics. 
• Dr. Satheesh is well versed in delicate procedures like bone marrow aspiration and biopsy, central line insertion, lumbar puncture and autologous stem cell transplantation.
• He also has vast experience in intraperitoneal chemotherapy, personalised medicine based on genomics and palliative care.
• Dr. Satheesh has so far handled more than 20000 cases.

Training and Certifications

• He also received extensive training in the essentials of palliative care and clinical placement in palliative care from IAPC.

Recognition

• Dr. Satheesh is involved in various clinical trials on cancer research and has a more than 50 number of national and international publications to his credit.

Publications

• FDG-PET Metabolic Vs CT Anatomical Monitoring of Tumour Response to Anterior Chemotherapy in Breast Carcinoma-The Uncertainties. Canc Therapy & Oncol Int J. 2021; 19(1): 556003.
• Landscape of clinically actionable mutations in breast cancer 'A cohort study'. Transl Oncol. 2021 Jan;14(1):100877.
• Translational relevance of baseline peripheral blood biomarkers to assess the efficacy of anti-programmed cell death 1 use in solid malignancies. J Cancer Res Ther. 2021 Jan-Mar;17(1):114-121.
• The future of lung cancer therapy: Striding beyond conventional EGFR and ALK treatments. Mol Clin Oncol. 2019 Apr;10(4):469-475.
• Intraperitoneal bevacizumab (Bev) for control of refractory malignant ascites. A single centre experience. Annals of Oncology 27 (Supplement 6): vi455–vi461, 2016.
• Genomic Profiling in Non-Small Cell Lung Cancer: New Hope for Personalized Medicine. Journal of Thoracic Oncology, Vol. 12, Issue 1, S974–S975: January 2017.
• Indian experience of Lenvatinib in radio-iodine refractory differentiated thyroid cancer. May 2018 Journal of Clinical Oncology 36(15_suppl) :e18107-e18107.
• Landscape of clinically actionable mutations in breast cancer ‘A cohort study’. January 2021, Translational Oncology 14(1):100877.

Other Doctors